BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. Nov 27, 2026; 18(11): 126504
Published online Nov 27, 2026. doi: 10.4254/wjh.126504
Clinical features and associated factors for clinically significant portal hypertension in patients with histologically early-stage primary biliary cholangitis
Hong-Xiao Hao, Xin Wei, Yao Lu, Lu Zhang, Yuan-Jiao Gao, Lei-Ping Hu, Xiao-Xue Chen, Meng-Jiao Xu, Wei-Hua Cao, Ru-Yu Liu, Ge Shen, Shu-Ling Wu, Ming-Hui Li, Yao Xie
Hong-Xiao Hao, Xin Wei, Yao Lu, Lu Zhang, Yuan-Jiao Gao, Lei-Ping Hu, Xiao-Xue Chen, Meng-Jiao Xu, Wei-Hua Cao, Ru-Yu Liu, Ge Shen, Shu-Ling Wu, Ming-Hui Li, Yao Xie, Department of Hepatology Second Division, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Co-first authors: Hong-Xiao Hao and Xin Wei.
Co-corresponding authors: Ming-Hui Li and Yao Xie.
Author contributions: Hao HX and Wei X conceived and designed the research framework, formulated the overall experimental scheme, collected samples, conducted experiments, curated raw data, and completed the preliminary data analysis and manuscript drafting, qualified as the co-first authors of the paper; Lu Y, Zhang L, Gao YJ, Hu LP, Chen XX, Xu MJ, Cao WH, Liu RY, Shen G and Wu SL performed literature retrieval, statistical analysis and visualization, and supplemented the discussion; Li MH and Xie Y supervised the entire research process, put forward key revisions and innovative viewpoints for the research design and manuscript content, reviewed and finalized the final version of the manuscript, and were responsible for the funding acquisition and project administration of the study, both authors played important and indispensable roles in the manuscript preparation as the co-corresponding authors; all authors read and approved the final manuscript and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
AI contribution statement: No AI tool was used to generate research data, interpret results, or formulate conclusions.
Supported by Beijing Research Ward Excellence Program, No. BRWEP2024W102170101; Beijing Municipal Health Commission High-Level Public Health Technical Personnel Construction Project, No. discipline leader-03-26; Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support, No. ZLRK202301; Beijing Hospitals Authority “Peak” Talent Training Program, No. DFL20241803; National Key Research and Development Program of China, No. 2023YFC2306900; and National Key Research and Development Program of Ministry of Science and Technology, No. 2023YFC2308105.
Institutional review board statement: The present clinical investigation obtained clearance from the Institutional Review Board at Beijing Ditan Hospital, Capital Medical University (approval No. DTEC-KY2026-097-01)
Informed consent statement: Informed consent was obtained from all participants.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: The datasets generated and/or analyzed during the current study are presented within the manuscript. The study protocol and statistical analysis code are available from the corresponding author upon reasonable request. However, data containing patient-identifying information cannot be shared upon individual request due to restrictions imposed by the institutional ethics committee to protect patient privacy and confidentiality.
Corresponding author: Ming-Hui Li, PhD, Professor, Department of Hepatology Second Division, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. wuhm2000@sina.com
Received: August 6, 2026
Revised: August 28, 2026
Accepted: November 9, 2026
Published online: November 27, 2026
Processing time: 105 Days and 5.5 Hours
Abstract
BACKGROUND

Clinically significant portal hypertension (CSPH) is traditionally associated with advanced liver fibrosis, but its occurrence and predictors in histologically early stage primary biliary cholangitis (PBC) remain unclear.

AIM

To identify clinical features and independent risk factors for CSPH in patients with biopsy proven early stage (Scheuer stage I–II) PBC, facilitating early recognition and targeted intervention.

METHODS

This retrospective study enrolled 110 patients with histologically early-stage PBC at Beijing Ditan Hospital (2020-2023). Patients were divided into CSPH (n = 27) and non CSPH (n = 83) groups based on Baveno VII criteria. Demographic, laboratory, elastographic, and ultrasonographic data were compared. Multivariate logistic regression was used to determine independent predictors.

RESULTS

Both groups were predominantly middle-aged women. The CSPH group had significantly lower white blood cell count, hemoglobin, platelet, albumin, cholinesterase, and low-density lipoprotein cholesterol levels, and higher total bilirubin, alkaline phosphatase, and total bile acid levels (all P < 0.05). Drug allergy history (29.6% vs 8.4%, P < 0.05) and histological stage II (63.0% vs 39.8%, P < 0.05) were more frequent in the CSPH group. Autoantibody profiles (anti-mitochondrial antibodies, antinuclear antibody, anti-centromere, anti-sp100, anti-gp210) and immunoglobulin levels did not differ between groups. Imaging showed larger portal vein diameter and higher liver stiffness in the CSPH group (both P < 0.05). Multivariate analysis identified drug allergies [odds ratio (OR) = 5.948, 95%CI: 1.494-23.675, P = 0.011] and main portal vein diameter (OR = 2.563, 95%CI: 1.635-4.017, P < 0.001) as independent factors associated with CSPH.

CONCLUSION

CSPH is not rare in histologically early-stage PBC, especially at stage II, and is accompanied by worse liver function and cytopenias. Drug allergy history and increased portal vein diameter are independently associated with CSPH, whereas common autoantibodies appear unrelated. These findings may help stratify early-stage PBC patients at risk of CSPH, though prospective validation is warranted.

Keywords: Primary biliary cholangitis; Histologically early-stage; Portal Hypertension; Clinically significant portal hypertension; Autoimmune liver disease; Associated factors; Retrospective studies

Core Tip: In early-stage primary biliary cholangitis, pre-cirrhotic clinically significant portal hypertension was common (24.5%). Drug-allergy history and wider main portal vein were independent risk factors, suggesting simple clues for risk stratification. However, the single-center retrospective design, modest sample, lack of hepatic venous pressure gradient (HVPG) confirmation, and short follow-up limit causal and prognostic inference. Routine care should include allergy history and ultrasound portal-vein monitoring; multicenter prospective HVPG-based studies are needed to validate prediction models.

Write to the Help Desk